Document Type
Article
Publication Date
11-5-2021
DOI
10.1001/jama.2021.20734
Abstract
The US Food and Drug Administration (FDA) granted Emergency Use Authorization for Pfizer-BioNTech’s mRNA COVID-19 vaccine (BNT162b2) for children 5 to 11 years of age on October 29, 2021. The Centers for Disease Control and Prevention recommended use of the vaccine among children in this age group on November 2, 2021. Approximately 28 million children are now eligible for vaccination, with only those younger than 5 years remaining excluded from vaccine eligibility. The benefits of pediatric COVID-19 vaccines are clear. Vaccinations protect children, decrease spread to families and communities, and ensure educational continuity. What do parents, practitioners, and policy makers need to know about pediatric COVID-19 vaccines?
Publication Citation
The Journal of the American Medical Association, published online November 7, 2021, at E1-E2.
Scholarly Commons Citation
Moss, William J.; Gostin, Lawrence O.; and Nuzzo, Jennifer B., "Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know" (2021). Georgetown Law Faculty Publications and Other Works. 2418.
https://scholarship.law.georgetown.edu/facpub/2418